Roper Technologies Inc.

▲ Bull Case

• ◆Neptune sold at $4-5B + AI monetization quantified = multiple re-rating to 35-38x: Neptune divestiture announced Q3-Q4 2026; $4B+ proceeds deployed in $2B+ buyback + acquisitions; AI monetization across portfolio begins to be disclosed (e.g., CentralReach AI adding $50M ARR in 12 months); ROP re-rates toward Constellation Software premium; adj. EPS $26 × 35x: $910 (+90%)
• ◆Organic growth reaccelerates to 8%+ (Deltek recovery + AI uplift): DOGE effects anniversary in H1 2026; Deltek revenues recover; AI-enabled workflow automation drives incremental ARR across Vertafore, CentralReach, Procare; total organic growth 8-9% vs. guided 5-6%; multiple expansion to 32-35x: $800-850 (+67-77%)
• ◆Large transformational acquisition in vertical SaaS: ROP acquires a $4-6B vertical SaaS platform (government, insurance, healthcare) at disciplined 18-22x EBITDA; immediately accretive to FCF; demonstrates M&A pipeline is open; Neptune proceeds + new debt fund it; incremental FCF adds $0.50-0.80 adj. EPS; combined with organic, EPS $27+: $900+ (+88%)

▼ Bear Case

• ◆DOGE extends + Deltek structurally impaired: Trump administration deepens government spending cuts; Deltek customer base (federal contractors) shrinks permanently; Deltek adj. EBITDA falls 30-40% and doesn't recover; Application Software segment loses its largest component; adj. EPS $18.50; P/E 25x: $462 (-4%)
• ◆Neptune sale fails at adequate valuation — remains a drag: Neptune's tariff exposure worsens; acquirers demand 8x EBITDA ($2.5-3B) vs. ROP's expectation of 10-12x ($3.5-4.5B); ROP holds Neptune; ongoing margin headwind; multiple stays depressed; adj. EPS $20; P/E 26x: $520 (+8% — modest upside with no multiple expansion)
• ◆AI disruption of vertical SaaS accelerates: AI-native competitors begin winning deals in government ERP (Deltek), insurance (Vertafore), and healthcare (CentralReach); churn rises from 5% to 8-10%; ROP's acquisition model breaks down as AI disrupts acquired businesses faster than new ones can be found; adj. EPS $15-17; multiple 22x: $330-374 (-22-31%)

“"Is ROP's discount to intrinsic value an opportunity (temporary headwinds) or a warning sign (structural impairment of the compounder model)?" Bull view: Roper's 20-year track record of 10-12%/yr adj. EPS CAGR is among the most consistent in S&P 500 history; the compounding machine rests on mission-critical vertical software with switching costs so high that customers don't leave even when cheaper alternatives exist; DOGE is real but temporary; Neptune divestiture at ~$4B would be accretive to the pure-software thesis; at 22x adj. EPS and 5.2% FCF yield, you are being paid to wait for the re-rating. Bear view: The $6B buyback is unusual for Roper — when management uses cash for buybacks rather than M&A, it implies the acquisition pipeline is thinning; AI disruption of vertical SaaS is real and accelerating (GitHub Copilot-style tools for Deltek ERP are 2-3 years away); DOGE may be a structural policy shift, not a typical 12-month spending cycle; ROP at $480 might be fairly valued, not cheap. Our view: The base rate for the bear view requires multiple coincident failures that each have individually low probabilities; the bear case itself (-4% to $462) shows the stock barely falls even if DOGE persists and Neptune is stuck; PWFV $685 vs. $480 is a 43% gap — BUY.”

• ◆Neptune strategic review decision (H2 2026, likely Q3-Q4) — sale at $4B+ is the single biggest re-rating catalyst; 55% probability of sale
• ◆Deltek Q2-Q3 FY2025 recovery signal (Jul-Oct 2026) — flat/positive revenue confirms DOGE is cyclical, not structural; 65% probability of improvement
• ◆Q2 FY2025 earnings + FY2025 guidance (~Aug 2026) — trajectory confirmation; 70% probability in-line or slight beat
• ◆AI monetization disclosure at portfolio level (Q3-Q4 FY2025) — even 2-3% ARR uplift = $140-210M incremental ARR at 15-20x multiple; 35% probability of meaningful disclosure by year-end
• ◆$6B buyback execution pace (quarterly) — sustained buyback at $480-520 is a persistent bull signal; 80% probability of continuation
• ◆DOGE effects anniversary (H1 2026) — 12-month mark signals normalization beginning; 60% probability
• ◆Large acquisition announcement — demonstrates M&A pipeline is open at disciplined 18-22x EBITDA pricing; 30% probability of major deal in FY2026

• ◆DOGE extends beyond 18 months and structurally impairs Deltek (~15% of revenue); 30% probability
• ◆Neptune sale fails at adequate price (>10x EBITDA); asset held as ongoing tariff/margin headwind; 45% probability
• ◆AI disruption of ROP vertical SaaS portfolio accelerates over 5-year horizon, driving churn from <5% to 8-10%; 30% probability
• ◆M&A overpayment on one deal at >25x EBITDA — capital discipline break that undermines the entire compounding model; 20% probability
• ◆Debt refinancing risk ($7.5B at 2026-2028 maturity) in elevated rate environment; 15% probability
• ◆Goodwill impairment on prior acquisition ($21.3B goodwill base); requires 10-15% value destruction across portfolio; 10% probability
• ◆Neil Hunn departure without clear internal succession — management IS the moat; 20% probability over 5-year horizon